Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Midscalp hair density and terminal hair percentage are good indicators of female pattern hair loss severity.

People with lower levels of free testosterone tend to have worse COVID-19 outcomes.

ULBP3 levels are higher in Tinea capitis patients and may help predict the disease's severity.

DNA variants can predict male pattern baldness, with higher risk scores increasing baldness likelihood.

The document concludes that managing hirsutism involves identifying the cause, using a scoring system for severity, combining cosmetic and medical treatments, encouraging weight loss, and providing psychological support, while noting the need for more research on drug treatments.

Scalp involvement is common in pemphigus and can lead to hair loss, with the severity of scalp lesions linked to overall disease severity.

Higher MIF levels in alopecia areata patients suggest it could be a treatment target and disease predictor.

High incidence of hair loss found in COVID-19 patients, but no severity correlation established.

Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.

Men with hair loss experience lower quality of life, worsened by factors like age, severity, and treatment history.

Hair pain is more common in women with hair loss, but it's not linked to the cause or severity of hair loss.

Methotrexate with steroids is slightly more effective than azathioprine with steroids for treating severe alopecia areata.

Low-dose oral isotretinoin improved hair loss and facial bumps in patients with a specific type of hair loss.

Monthly PRP therapy is more effective than daily minoxidil for alopecia areata.

Combining calcipotriol and PRP is most effective for treating Alopecia Areata.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Baricitinib is effective and safe for treating severe alopecia areata.

Alopecia areata seriously lowers quality of life, especially affecting self-image, mental health, and social life.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.

An extra-strength marine protein supplement helped increase hair growth and decrease hair shedding in women with thinning hair.

Researchers created a fast, accurate computer program to measure hair loss in alopecia areata patients.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

Hair loss in Chinese college students leads to various psychological issues, so treatment should address both hair loss and mental health.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Spironolactone is a low-cost, effective, and generally safe treatment for various skin conditions related to hormones.

Hair loss lowers quality of life, causing embarrassment, frustration, and sexual rejection.

Japanese patients with alopecia areata often have a higher BMI and consume more vitamin C, fruit, and retinol, which may affect their condition's development or severity.